PeterM.IzmirlyMD
Rheumatology • New York, NYAssistant Professor, Medicine, New York University School of Medicine
Dr. Izmirly is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
560 1st Ave
# Nyu
New York, NY 10016Phone+1 212-263-0745
Education & Training
NYU Grossman School of MedicineFellowship, Rheumatology, 2004 - 2007- NYU Grossman School of MedicineResidency, Internal Medicine, 2001 - 2004
- New York University School of MedicineClass of 2001
Certifications & Licensure
NY State Medical License 2002 - 2026- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- 182 citationsMaternal and Fetal Factors Associated With Mortality and Morbidity in a Multi–Racial/Ethnic Registry of Anti-SSA/Ro–Associated Cardiac Neonatal LupusPeter M. Izmirly, Amit Saxena, Mimi Y. Kim, Dan Wang, Sara Sahl
Circulation. 2011-11-01 - 62 citationsPrevention and treatment in utero of autoimmune-associated congenital heart block.Amit Saxena, Peter M. Izmirly, Barbara Mendez, Jill P. Buyon, Deborah M. Friedman
Cardiology in Review. 2014-11-01 - 175 citationsThe clinical spectrum of autoimmune congenital heart blockPilar Brito-Zerón, Peter M. Izmirly, Manuel Ramos-Casals, Jill P. Buyon, Munther A. Khamashta
Nature Reviews. Rheumatology. 2015-05-01
Journal Articles
- A Prospective International Study on Adherence to Treatment in 305 Patients with Flaring SLE: Assessment by Drug Levels and Self‐Administered QuestionnairesPeter Izmirly, Michelle Petri, Meenakshi Jolly, Jill Buyon, Clinical Pharmacology & Therapeutics
Authored Content
- Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive MothersJuly 2020
- Tubulointerstitial Damage Predicts End Stage Renal Disease in Lupus Nephritis with Preserved to Moderately Impaired Renal Function: A Retrospective Cohort StudyFebruary 2018
Press Mentions
COVID-19 Booster Vaccine Beneficial for Lupus Patients: StudyJuly 13th, 2022- Patients with Lupus Benefit from COVID-19 Vaccine Booster – ScienceDailyJuly 13th, 2022
- NYU Langone Joins NIH-Sponsored Program as Leading Center to Discover New Targets for Autoimmune, Inflammatory DiseasesMarch 30th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
